MDxHealth Q2 FY26 net loss widens 36% to USD 9.5 million; revenue rises 16% to USD 27.2 million - MDXH News | RalliesMDxHealth Q2 FY26 net loss widens 36% to USD 9.5 million; revenue rises 16% to USD 27.2 million
M
MDXH• Q2 results and outlook
- MDxHealth posted Q2 revenue up 16% to USD 27.2 million, rising USD 3.3 million sequentially from Q1.
- Operating loss more than doubled to USD 5.1 million, due to higher operating expenses tied to the ExoDx acquisition.
- Net loss widened 36% to USD 9.5 million; IFRS loss per share increased to USD 0.18.
- Adjusted EBITDA turned negative at USD 2.3 million versus positive a year earlier; period-end cash totaled USD 19.2 million.
- Maintained 2026 revenue guidance of USD 110-115 million; Resolve wind-down completed, with all customers transitioned by June 30.
